Model design
TNBC
TreeAge Pro 2019 (TreeAge, Williamstown, Massachusetts) was used for the Markov model building. The parameters included in this analysis are presented in Table A decision tree analytic model based on a transitional Markov chain with clinical data from the Olympia trial and other studies was developed to estimate the costs and benefits of the germline BRCA mutation testing for a representative cohort of TNBC and HR-positive HER2-negative BC patients based mainly on the baseline demographic and clinical characteristics of the OlympiA trial [